Your browser doesn't support javascript.
Carbohydrate fatty acid monosulphate: oil-in-water adjuvant enhances SARS-CoV-2 RBD nanoparticle-induced immunogenicity and protection in mice.
Nanishi, Etsuro; Borriello, Francesco; Seo, Hyuk-Soo; O'Meara, Timothy R; McGrath, Marisa E; Saito, Yoshine; Chen, Jing; Diray-Arce, Joann; Song, Kijun; Xu, Andrew Z; Barman, Soumik; Menon, Manisha; Dong, Danica; Caradonna, Timothy M; Feldman, Jared; Hauser, Blake M; Schmidt, Aaron G; Baden, Lindsey R; Ernst, Robert K; Dillen, Carly; Yu, Jingyou; Chang, Aiquan; Hilgers, Luuk; Platenburg, Peter Paul; Dhe-Paganon, Sirano; Barouch, Dan H; Ozonoff, Al; Zanoni, Ivan; Frieman, Matthew B; Dowling, David J; Levy, Ofer.
  • Nanishi E; Precision Vaccines Program, Boston Children's Hospital, Boston, MA, USA.
  • Borriello F; Department of Pediatrics, Harvard Medical School, Boston, MA, USA.
  • Seo HS; Precision Vaccines Program, Boston Children's Hospital, Boston, MA, USA.
  • O'Meara TR; Department of Pediatrics, Harvard Medical School, Boston, MA, USA.
  • McGrath ME; Division of Immunology, Boston Children's Hospital, Boston, MA, USA.
  • Saito Y; Generate Biomedicines, Cambridge, MA, USA.
  • Chen J; Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, MA, USA.
  • Diray-Arce J; Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, Boston, MA, USA.
  • Song K; Precision Vaccines Program, Boston Children's Hospital, Boston, MA, USA.
  • Xu AZ; Department of Microbiology and Immunology, Center for Pathogen Research, University of Maryland School of Medicine, Baltimore, MD, USA.
  • Barman S; Precision Vaccines Program, Boston Children's Hospital, Boston, MA, USA.
  • Menon M; Research Computing Group, Boston Children's Hospital, Boston, MA, USA.
  • Dong D; Precision Vaccines Program, Boston Children's Hospital, Boston, MA, USA.
  • Caradonna TM; Department of Pediatrics, Harvard Medical School, Boston, MA, USA.
  • Feldman J; Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, MA, USA.
  • Hauser BM; Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, MA, USA.
  • Schmidt AG; Precision Vaccines Program, Boston Children's Hospital, Boston, MA, USA.
  • Baden LR; Department of Pediatrics, Harvard Medical School, Boston, MA, USA.
  • Ernst RK; Precision Vaccines Program, Boston Children's Hospital, Boston, MA, USA.
  • Dillen C; Precision Vaccines Program, Boston Children's Hospital, Boston, MA, USA.
  • Yu J; Ragon Institute of MGH, MIT, and Harvard, Cambridge, MA, USA.
  • Chang A; Ragon Institute of MGH, MIT, and Harvard, Cambridge, MA, USA.
  • Hilgers L; Ragon Institute of MGH, MIT, and Harvard, Cambridge, MA, USA.
  • Platenburg PP; Ragon Institute of MGH, MIT, and Harvard, Cambridge, MA, USA.
  • Dhe-Paganon S; Department of Microbiology, Harvard Medical School, Boston, MA, USA.
  • Barouch DH; Department of Medicine, Brigham and Women's Hospital, Boston, MA, USA.
  • Ozonoff A; Department of Microbial Pathogenesis, University of Maryland School of Dentistry, Baltimore, MD, USA.
  • Zanoni I; Department of Microbiology and Immunology, Center for Pathogen Research, University of Maryland School of Medicine, Baltimore, MD, USA.
  • Frieman MB; Center for Virology and Vaccine Research, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USA.
  • Dowling DJ; Center for Virology and Vaccine Research, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USA.
  • Levy O; LiteVax B.V, Oss, The Netherlands.
NPJ Vaccines ; 8(1): 18, 2023 Feb 14.
Article in English | MEDLINE | ID: covidwho-2243664
ABSTRACT
Development of SARS-CoV-2 vaccines that protect vulnerable populations is a public health priority. Here, we took a systematic and iterative approach by testing several adjuvants and SARS-CoV-2 antigens to identify a combination that elicits antibodies and protection in young and aged mice. While demonstrating superior immunogenicity to soluble receptor-binding domain (RBD), RBD displayed as a protein nanoparticle (RBD-NP) generated limited antibody responses. Comparison of multiple adjuvants including AddaVax, AddaS03, and AS01B in young and aged mice demonstrated that an oil-in-water emulsion containing carbohydrate fatty acid monosulphate derivative (CMSO/W) most effectively enhanced RBD-NP-induced cross-neutralizing antibodies and protection across age groups. CMSO/W enhanced antigen retention in the draining lymph node, induced injection site, and lymph node cytokines, with CMS inducing MyD88-dependent Th1 cytokine polarization. Furthermore, CMS and O/W synergistically induced chemokine production from human PBMCs. Overall, CMSO/W adjuvant may enhance immunogenicity and protection of vulnerable populations against SARS-CoV-2 and other infectious pathogens.
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: Available Collection: International databases Database: MEDLINE Type of study: Experimental Studies / Randomized controlled trials / Systematic review/Meta Analysis Topics: Vaccines Language: English Journal: NPJ Vaccines Year: 2023 Document Type: Article Affiliation country: S41541-023-00610-4

Similar

MEDLINE
LILACS
LIS
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: Available Collection: International databases Database: MEDLINE Type of study: Experimental Studies / Randomized controlled trials / Systematic review/Meta Analysis Topics: Vaccines Language: English Journal: NPJ Vaccines Year: 2023 Document Type: Article Affiliation country: S41541-023-00610-4